LXRX Lexicon Pharmaceuticals, Inc. Stock Quote

LXRX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.05	Insider Own	3.10%	Shs Outstand	107.31M	Perf Week	5.71%
Market Cap	1.41B	Forward P/E	-	EPS next Y	-0.69	Insider Trans	425.63%	Shs Float	47.02M	Perf Month	139.72%
Income	-104.20M	PEG	-	EPS next Q	-0.29	Inst Own	91.30%	Short Float	25.51%	Perf Quarter	512.23%
Sales	32.50M	P/S	43.41	EPS this Y	197.90%	Inst Trans	19.23%	Short Ratio	1.07	Perf Half Y	367.58%
Book/sh	0.82	P/B	10.38	EPS next Y	26.30%	ROA	-32.30%	Target Price	3.67	Perf Year	147.02%
Cash/sh	0.67	P/C	12.65	EPS next 5Y	-	ROE	-167.50%	52W Range	1.03 - 9.40	Perf YTD	148.83%
Dividend	-	P/FCF	-	EPS past 5Y	23.30%	ROI	40.70%	52W High	-9.47%	Beta	2.00
Dividend %	-	Quick Ratio	1.50	Sales past 5Y	69.70%	Gross Margin	91.70%	52W Low	726.21%	ATR	0.81
Employees	184	Current Ratio	1.50	Sales Q/Q	-97.80%	Oper. Margin	-	RSI (14)	78.63	Volatility	13.40% 15.02%
Optionable	Yes	Debt/Eq	0.23	EPS Q/Q	-63.70%	Profit Margin	-	Rel Volume	0.33	Prev Close	8.48
Shortable	No	LT Debt/Eq	0.13	Earnings	Oct 29 BMO	Payout	-	Avg Volume	11.22M	Price	8.51
Recom	2.30	SMA20	83.06%	SMA50	175.33%	SMA200	304.49%	Volume	3,733,231	Change	0.35%

Dec-08-20

Upgrade

Citigroup

Neutral → Buy

Nov-18-20

Upgrade

Gabelli & Co

Hold → Buy

Dec-11-19

Downgrade

Gabelli & Co

Buy → Hold

Nov-08-19

Downgrade

Citigroup

Buy → Neutral

$3 → $4

Sep-11-19

Upgrade

Gabelli & Co

Hold → Buy

Jul-29-19

Downgrade

Stifel

Buy → Hold

$10 → $4

Mar-25-19

Upgrade

Gabelli & Co

Sell → Hold

Jul-31-18

Reiterated

Stifel

Buy

$24 → $23

Feb-23-18

Downgrade

Needham

Buy → Hold

Feb-14-18

Downgrade

JP Morgan

Neutral → Underweight

$10

Mar-01-17

Reiterated

Wedbush

Outperform

$33 → $38

Mar-01-17

Reiterated

H.C. Wainwright

Buy

$26 → $27

Oct-07-16

Initiated

H.C. Wainwright

Buy

$26

Aug-05-16

Reiterated

Wedbush

Outperform

$30 → $31

Aug-02-16

Initiated

Citigroup

Buy

$21

Mar-02-16

Reiterated

Wedbush

Outperform

$26 → $28

Nov-09-15

Reiterated

Wedbush

Outperform

$19 → $26

Sep-28-15

Upgrade

Gabelli & Co

Sell → Hold

Sep-18-15

Downgrade

Gabelli & Co

Hold → Sell

Aug-10-15

Downgrade

JP Morgan

Overweight → Neutral

Jan-22-21 10:18AM	AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study Zacks
Jan-20-21 12:13PM	Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates Zacks
Jan-15-21 08:31AM	Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA Zacks -14.66%
Jan-14-21 08:00AM	Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure GlobeNewswire +105.36%
Jan-06-21 08:00AM	Lexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-21 09:40AM	Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study Zacks
Dec-31-20 08:00AM	Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia GlobeNewswire
06:11AM	Moving Average Crossover Alert: Lexicon Pharmaceuticals (LXRX) Zacks
Dec-16-20 04:05PM	Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience GlobeNewswire
Dec-12-20 04:03PM	Is LXRX A Good Stock To Buy Now? Insider Monkey
Dec-11-20 06:04PM	Why Lexicon Pharmaceuticals Flopped on Friday Motley Fool -6.02%
08:02AM	Lexicon Announces Offering of Common Stock GlobeNewswire
07:38AM	Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain GlobeNewswire
Dec-09-20 09:22AM	Is the Options Market Predicting a Spike in Lexicon Pharmaceuticals (LXRX) Stock? Zacks -5.84%
Nov-16-20 10:02PM	Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine GlobeNewswire
08:00AM	Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference GlobeNewswire
Nov-06-20 07:48AM	Analysts Just Shipped A Huge Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Estimates Simply Wall St.
Oct-29-20 10:05AM	Lexicon Pharmaceuticals (LXRX) Q3 Earnings Beat Estimates Zacks
08:02AM	Lexicon Pharmaceuticals: Q3 Earnings Insights Benzinga
06:00AM	Lexicon Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:00AM	Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update GlobeNewswire
Oct-27-20 08:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020 GlobeNewswire
Sep-23-20 06:43PM	Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness GlobeNewswire
Sep-14-20 09:46AM	A Look Into Healthcare Sector Value Stocks Benzinga +5.23%
Sep-08-20 04:05PM	Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics GlobeNewswire
Sep-04-20 08:00AM	Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain GlobeNewswire
Sep-03-20 06:00PM	Lexicon Pharmaceuticals to Participate in the Citi 15 Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference GlobeNewswire
Aug-24-20 11:35AM	A Look Into Healthcare Sector Value Stocks Benzinga
Aug-10-20 11:52AM	5 Value Stocks To Watch In The Healthcare Sector Benzinga
Aug-03-20 07:25AM	GTCR and TerSera Therapeutics Announce Acquisition of Xermelo PR Newswire
Aug-02-20 09:54AM	What You Need To Know About The Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Downgrade Today Simply Wall St.
Jul-30-20 06:00PM	Lexicon Pharmaceuticals Inc (LXRX) Q2 2020 Earnings Call Transcript Motley Fool +14.94%
03:52PM	Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment? Simply Wall St.
10:55AM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:15AM	Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program GlobeNewswire
07:10AM	Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO GlobeNewswire
07:00AM	Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update GlobeNewswire
Jul-23-20 07:00AM	Lexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020 GlobeNewswire -5.70%
Jul-22-20 12:32PM	Earnings Preview: Lexicon Pharmaceuticals (LXRX) Q2 Earnings Expected to Decline Zacks -6.99%
Jul-21-20 07:00AM	Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes GlobeNewswire
Jul-20-20 07:00AM	Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference GlobeNewswire
Jul-14-20 01:19PM	5 Health Care Stocks Trading With Low Price-Earnings Ratios GuruFocus.com
Jul-04-20 02:02PM	Should You Buy Lexicon Pharmaceuticals, Inc. (LXRX)? Insider Monkey
Jun-13-20 11:01AM	Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions GlobeNewswire
Jun-11-20 05:22PM	Edited Transcript of LXRX earnings conference call or presentation 27-Apr-20 12:00pm GMT Thomson Reuters StreetEvents -6.47%
May-27-20 07:00AM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-13-20 05:30PM	Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyls Antiproliferative Effects Against Various Cancer Cell Lines GlobeNewswire
Apr-27-20 06:33PM	US Indexes Start the Week Higher GuruFocus.com +12.20%
04:24PM	Why Lexicon Pharmaceuticals Stock Soared Today Motley Fool
08:15AM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:43AM	Lexicon Pharmaceuticals: Q1 Earnings Insights Benzinga
07:00AM	LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE GlobeNewswire
Apr-22-20 05:41PM	Lexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast On April 27, 2020 GlobeNewswire -5.10%
Apr-20-20 10:04AM	The Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Is Down 88% So Some Shareholders Are Rather Upset Simply Wall St.
Apr-07-20 07:00AM	LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020 GlobeNewswire -5.91%
Mar-30-20 11:11AM	Edited Transcript of LXRX earnings conference call or presentation 12-Mar-20 12:00pm GMT Thomson Reuters StreetEvents
Mar-20-20 07:44AM	The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company Benzinga -14.83%
Mar-19-20 04:01PM	LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM GlobeNewswire
Mar-13-20 08:05AM	LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYLS ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME GlobeNewswire +5.18%
Mar-12-20 01:40PM	Lexicon Pharmaceuticals: Q4 Earnings Insights Benzinga -14.98%
09:35AM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:00AM	LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE GlobeNewswire
Mar-05-20 07:00AM	Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020 GlobeNewswire -6.46%
Mar-04-20 12:30PM	Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for Zacks
Jan-24-20 03:00PM	Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyls Antiproliferative Effects in Patients With Carcinoid Syndrome GlobeNewswire
Jan-20-20 04:01PM	Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium GlobeNewswire
08:07AM	Is Lexicon Pharmaceuticals (NASDAQ:LXRX) Using Too Much Debt? Simply Wall St.
Jan-09-20 02:50PM	Top Biotech Stocks for Q1 2020 Investopedia
Jan-06-20 06:09PM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Dec-20-19 08:31AM	Lexicon shares fall on diabetes study data MarketWatch
07:00AM	Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes GlobeNewswire
Dec-19-19 08:28PM	Were Hedge Funds Right About Betting On Lexicon Pharmaceuticals, Inc. (LXRX)? Insider Monkey
Dec-13-19 08:52AM	Implied Volatility Surging for Lexicon (LXRX) Stock Options Zacks
Dec-05-19 12:54PM	How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? Simply Wall St. +12.20%
07:00AM	Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 GlobeNewswire
Dec-03-19 07:00AM	Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer GlobeNewswire
Dec-02-19 11:09AM	Why Lexicon Pharma Shares Are Moving Lower Benzinga -10.48%
09:57AM	FDA denies appeal of decision over Lexicon Pharmas diabetes drug Yahoo Finance Video
07:58AM	UPDATE: Lexicon Pharmaceuticals stock slides 31% after FDA denies appeal of decision relating to diabetes drug MarketWatch
07:00AM	Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDAs Office of New Drugs for Sotagliflozin in Type 1 Diabetes GlobeNewswire
Nov-26-19 04:01PM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire -6.02%
Nov-15-19 11:17PM	Edited Transcript of LXRX earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 08:09PM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
09:10AM	Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now? Zacks
Nov-13-19 08:39AM	Top Ranked Value Stocks to Buy for November 13th Zacks
Nov-07-19 11:15AM	Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates Zacks
07:00AM	Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Oct-31-19 04:01PM	Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 GlobeNewswire
10:34AM	Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth Zacks
Oct-30-19 10:34AM	Is Lexicon Pharmaceuticals, Inc. (LXRX) Going to Burn These Hedge Funds? Insider Monkey
Oct-29-19 07:05AM	NASDAQ: LXRX Investor Notice: Update in Lawsuit against Lexicon Pharmaceuticals, Inc. announced by Shareholders Foundation ACCESSWIRE
Oct-15-19 11:29AM	Introducing Lexicon Pharmaceuticals (NASDAQ:LXRX), The Stock That Tanked 80% Simply Wall St.
Oct-13-19 05:15PM	New Sanofi CEO Looks to Shake Things Up GuruFocus.com
Oct-02-19 04:01PM	Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium GlobeNewswire
Sep-30-19 10:05AM	Small Caps Win in September: 5 Best ETFs & Stocks Zacks -12.37%
Sep-23-19 08:54AM	Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock? Zacks -5.62%
Sep-18-19 08:42AM	Lexicon (LXRX) Catches Eye: Stock Jumps 7.3% Zacks +29.25%
Sep-15-19 11:18AM	The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck Benzinga
Sep-11-19 07:42PM	Woodlands-based pharma co. to receive $260M in drug dispute settlement American City Business Journals +27.91%
09:46AM	Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally Zacks

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Artal International S.C.A.	Director	Dec 16	Buy	3.20	10,937,500	35,000,000	32,259,461	Dec 17 02:43 PM
Invus Public Equities, L.P.	Director	Dec 16	Buy	3.20	10,937,500	35,000,000	32,259,461	Dec 17 02:39 PM
SOBECKI CHRISTOPHER J	Director	Apr 26	Option Exercise	0.00	3,466	0	140,759	Apr 27 04:48 PM
Swain Judith L	Director	Apr 26	Option Exercise	0.00	3,466	0	16,368	Apr 27 04:49 PM
Palantoni Frank	Director	Apr 26	Option Exercise	0.00	3,466	0	16,368	Apr 27 04:48 PM
NIES ALAN S	Director	Apr 26	Option Exercise	0.00	3,466	0	17,082	Apr 27 04:47 PM
DEBBANE RAYMOND	Director	Apr 26	Option Exercise	0.00	3,466	0	316,883	Apr 27 04:45 PM
LEFKOWITZ ROBERT J MD	Director	Apr 26	Option Exercise	0.00	3,466	0	16,368	Apr 27 04:46 PM
BARKER SAM L	Director	Apr 26	Option Exercise	0.00	3,466	0	55,653	Apr 27 04:44 PM
Amouyal Philippe	Director	Apr 26	Option Exercise	0.00	3,466	0	16,368	Apr 27 04:43 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience